MedTrace Logo

Oral Vitamin C Administration on Erythropoietin Dosing Requirement in End-Stage Renal Disease Patients on Regular Hemodialysis

NCT07076108 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-12-18

No results posted yet for this study

Summary

The study aimed to evaluate the safety and efficacy of oral vitamin C administration on erythropoietin dosing requirement in end-stage renal disease patients on regular hemodialysis.

Conditions

  • Vitamin C
  • Oral Administration
  • Erythropoietin
  • End-Stage Renal Disease
  • Regular Hemodialysis

Interventions

DRUG

Normal regimen of treatment of anemia

Patients were on normal regimen of treatment of anemia.

DRUG

Vitamin C

Patients were on 250 mg oral vitamin C daily for 3 months.

DRUG

Vitamin C

Patients were on 500 mg oral vitamin C daily for 3 months.

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-01
Primary Completion
2024-04-28
Completion
2024-04-28

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07076108 on ClinicalTrials.gov